

Lipigon Q2 2024 - Marea Launched

Redeye comments on Lipigon's Q2 report 2024. The most significant event since our last update was the launch of Marea Therapeutics. We discuss how patient recruitment to the phase II study of Lipisense is ongoing and why it appears to have been slightly delayed.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Lipigon Q2 2024 - Marea Launched